长链非编码RNA CCAT1可作为肝细胞癌血浆标志物并预测其治疗效果  

Long non-coding RNA CCAT1 as a plasma biomarker for hepatocellular carcinoma can be used to predict the therapeutic effect

作　　者：张彬彬 郁皓 曹斐 吴晓霞 单永锋 王昊楠 刘慧 ZHANG Bin-bin;YU Hao;CAO Fei;WU Xiao-xia;SHAN Yong-feng;WANG Hao-nan;LIU Hui(Department of Oncology,the Fifth People′s Hospital of Wuxi,Wuxi 214000,Jiangsu,China)

机构地区：[1]无锡市第五人民医院肿瘤科,江苏214000

出　　处：《肝脏》2021年第4期392-394,共3页Chinese Hepatology

基　　金：无锡市科技局指导性项目。

摘　　要：目的本研究旨在评价长链非编码RNA(lncRNA)结肠癌相关转录因子1(CCAT1)在肝细胞癌(HCC)患者血液中的表达水平,及其介入或射频治疗前后的变化,探讨其作为HCC的诊断或预后标志物的可能性。方法收集66例HCC患者及50例健康成人血液标本,其中37例HCC患者经介入或射频治疗,同时收集治疗后1个月左右血液标本,应用qRT-PCR方法分别检测HCC患者和健康成人对照组血液中CCAT1表达水平,比较了37例HCC患者介入或射频治疗后的CCAT1表达水平。结果CCAT1在HCC患者血液中的表达水平高于正常对照组(P=0.016),其ROC曲线下面积为0.782(95%CI:0.692~0.873,P<0.001),对HCC的诊断有一定的价值。37例HCC患者经射频消融或肝动脉介入治疗后血浆中CCAT1表达水平较治疗前下降(P=0.003)。临床病例特征分析发现,血浆中CCAT1的表达水平越高则HCC患者的BCLC分期越高。结论本研究显示CCAT1在HCC患者血浆中高表达,可作为HCC的血浆标志物,并可预测其治疗效果。Objective To assess the expression level of long non-coding ribose nucleic acid(lnc RNA)colon cancer associated transcript-1(CCAT1)in the peripheral blood of patients with hepatocellular carcinoma(HCC)and its changes before and after interventional or radiofrequency treatment,and to explore its potential as a diagnostic or prognostic biomarker for HCC.Methods Blood samples were collected from 66 HCC patients and 50 healthy controls,among whom 37 HCC patients received interventional or radiofrequency treatment.Reverse-transcription polymerase chain reaction was used to detect the CCAT1 levels.The expression levels of CCAT1 were compared between HCC patients and healthy controls,as well as before and 1 month after intervention or radiofrequency therapy in HCC patients.Results The level of CCAT1 was significantly higher in HCC patients than that in healthy controls(P=0.016).The area under the receiver operating characteristic(ROC)curve of CCAT1 for the diagnosis HCC was 0.782(95%confidence interval:0.692-0.873,P<0.001).The expression level of CCAT1 of 37 patients with HCC was decreased after radiofrequency ablation or interventional treatment(P=0.003).High expression of plasma CCAT1 was significantly associated with advanced Barcelona Clinic Liver Cancer(BCLC)stage.Conclusion The expression level of CCTA1 can be used as a noninvasive biomarker for HCC and help to predict therapeutic efficacy.

关 键 词：肝细胞癌 长链非编码RNA 血浆 肿瘤标志物 CCAT1 

分 类 号：R73[医药卫生—肿瘤]